New Hope for Serious Infections

Cidara is a clinical-stage biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections.

Company OverviewRezafunginCloudbreak Antivirals

Cidara is a clinical-stage biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections.

About UsRezafunginCloudbreak Antivirals

Cidara News + Events

Applying the Principles of Immunotherapy to Infectious Diseases
Read on Pharma's Almanac

There is an urgent and growing need not only for improved anti-infectives but also for entirely new therapeutic approaches to treat and prevent fungal and viral pathogens, particularly for today’s increasingly complex and immunocompromised patients.

Our initial portfolio is comprised of proprietary product and development candidates for the treatment and prevention of serious infections.

Rezafungin

Rezafungin, a long-acting echinocandin antifungal, is the only once-weekly product candidate in development for the treatment and prevention of life-threatening invasive fungal disease.

Cloudbreak Antiviral Platform

The Cloudbreak antiviral platform is a fundamentally new approach to the fight against life-threatening infectious disease that provides potent antiviral activity and immune system engagement in a single molecule.